A Biologic Is Grown, Not Written Down

A small molecule has a structure you can draw and synthesise.

A production cell line is selected over months and then banked for decades.

What cells are fed, why the formulation is proprietary, and how a media change propagates into the product.

Agitation, aeration, pH, temperature and the fact that shear kills.

Grams per litre as the headline number of upstream.

The affinity step that pulls the antibody out of everything else, and the resin that costs more per litre than most people expect.

Aggregates, host-cell protein, DNA and leached ligand.

Demonstrating that the process removes what it must, using deliberately spiked runs.

Recovery multiplies down the train.

The unglamorous logistics of making and moving thousands of litres of solution, and why buffer management constrains plant design.

Fill-finish has no rework: whatever goes into the vial is the product.

Removing water to make a protein stable on a shelf.

Glass, stopper and seal as part of the formulation.

Particulate inspection at scale — automated and human — and what counts as a defect.

A biologic cannot be verified by a single structure.

Measuring what the molecule does rather than what it is, and why these assays are the hardest to make reproducible.

Post-translational modification that the cells decide and the process influences — and that changes how the drug behaves.

Shelf life cannot be simulated away.

Phase one asks whether it is tolerated, phase two whether it does anything, phase three whether it does it better than what exists.

What a trial measures determines what it can conclude.

Efficacy, safety, recruitment and design.

Comparability: proving that material made after a change is the same product.

Mixing, oxygen transfer and heat do not scale linearly.

Disposable bags and tubing against stainless steel: what it removed, what it introduced, and how it altered what a facility looks like.

Moving a process between sites and the enormous amount of implicit knowledge that does not travel in a document.

Facility fit, campaign scheduling and why capacity is a calendar problem as much as a volume one.